Suffice it to say, it has been a banner week in the world of stem cells. In this rapidly-changing market environment, it can be difficult to keep up with current events. To help you out, we’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think! [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Cord Blood Market Consolidation Continues as “FamilyCord” Acquires Southern Cord Inc.
On November 13, 2015, AlphaCord released news that it was acquiring LifeSource Cryobank. The acquisition was AlphaCord’s fifth acquisition of smaller cord blood banks. Today, California Cryobank Stem Cell Services LLC, better known as “FamilyCord”, announced it has acquired Southern Cord Inc., a cord blood bank operating within the southeastern U.S.
Together, these recent mergers continue the trend of consolidation within the global cord blood banking market. [Read more…]
Gamida Cell Presents Additional Positive Data of NiCord® in Blood Cancer Patients
Headquartered in Israel, Gamida Cell is innovative company that has become well-known for its unique approaches to hematopoietic stem cell (HSC) therapeutics. Although a small company at the time, Gamida Cell broke onto the global scene in 2003 when it announced a Phase I trial of its StemEx™ product for the treatment of leukemia and lymphoma patients.
StemEx™ was Gamida Cell’s first generation product for theex vivo (“outside the body”) expansion of cord blood stem cells, which can be utilized in hematopoietic stem cell transplantation (HSCT) to treat high risk cancers. [Read more…]
UPDATE: FDA to Schedule “Scientific Workshop” for Draft Guidances Pertaining to Regulation of Stem Cells
Recently, we released a post titled “The Good, The Bad, and The Ugly of the Postponed FDA Public Hearing (Part 15) – Draft Guidances Controlling Stem Cells.” In that article, we explored the overwhelming response received by the FDA for participation in an event intended to review four draft guidances controlling the regulation of human cells and tissues within the U.S.
With approximately 600 registrations for the events and 100 people and groups interested in presenting, it was clear that people across the United States are substantially concerned about the draft guidances that appear to be a further restriction on stem cell therapy within the U.S. [Read more…]
Cord Blood Banking Dynamics within India? Cesca Therapeutics’ Indian Subsidiary Expands
The cord blood banking market is an interesting market, as its rate of growth has slowed over the past couple years. When the market is assessed by the number of cord blood units stored, cord tissue units banked, and number of units transplanted, there are regions that are experiencing growth and regions in decline. In particular, cord blood markets are experiencing strong growth within Asia, are relatively flat within North America, and are in decline within Europe. Additionally, cord blood banks within Europe have been some of the most proactive banks to expand into other areas of stem cell storage. [Read more…]
- « Previous Page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- …
- 62
- Next Page »